Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04261075
Title IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors MedImmune LLC

Advanced Solid Tumor


Durvalumab + IPH5201 + Oleclumab

Durvalumab + IPH5201


Age Groups: adult | senior
Covered Countries USA | FRA | ESP

No variant requirements are available.